In the following video, Motley Fool health-care analyst David Williamson takes a look back at Vertex's (VRTX -1.65%) earnings report this quarter. While it was far from a good quarter for the company, things were somewhat better than expected, leading to a sell-off that wasn't nearly as bad as analysts had feared. David tells us why the company struggled this quarter, and what investors can expect from them in the months to come.
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Foolish Review: Vertex Earnings
NASDAQ: VRTX
Vertex Pharmaceuticals

A look at how Vertex performed this quarter.
David Williamson has no position in any stocks mentioned. The Motley Fool recommends Gilead Sciences, Johnson & Johnson, and Vertex Pharmaceuticals. The Motley Fool owns shares of Johnson & Johnson. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Stocks Mentioned




*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles





Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.